Our mission is to revolutionize our ability to interrogate deubiquitinase (DUB) biology, validate DUBs as therapeutic targets, and develop small molecule-based ligands suitable for clinical development. To accomplish this, we have established an integrated DUB-centric platform comprised of DUB-targeted libraries with novel scaffolds and chemotypes and a suite of established and novel biochemical and chemoproteomic assays to profile compound activity and selectivity, as well as expertise in DUB medicinal chemistry, structural biology, computational chemistry, and functional annotation.